The Frontotemporal Dementia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Frontotemporal Dementia Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Frontotemporal Dementia Market.

Some of the key takeaways from the Frontotemporal Dementia Pipeline Report:

• Companies across the globe are diligently working toward developing novel Frontotemporal Dementia treatment therapies with a considerable amount of success over the years. 
• Frontotemporal Dementia companies working in the treatment market are Deep Genomics, AcuraStem, Asceneuron SA, AviadoBio, CNS therapeutics, CAMP4 Therapeutics, Neurimmune, Wave Life Sciences, Passage Bio, Prevail Therapeutics, Transposon Therapeutics, Alector Inc, and others, are developing therapies for the Frontotemporal Dementia treatment 

• Emerging Frontotemporal Dementia therapies in the different phases of clinical trials are- Research programme CNS Therapies, AS-203, M1 PAM, AVB PGRN, NI308, WVE-004, PBFT02, PR006, TPN-101, AL001, and others are expected to have a significant impact on the Frontotemporal Dementia market in the coming years.  
• In February 2022, The completion of a Series B fundraising for $64 million was announced by Arkuda Therapeutics. Eli Lilly and Company, Surveyor Capital (a Citadel company), and Pivotal bioVenture Partners joined the financing as co-lead investors, along with previous backers Atlas Venture, Pfizer Ventures, funds managed by Tekla Capital Management LLC, and Mission BioCapital
• In January 2022, The Association for Frontotemporal Degeneration (AFTD) and the Alzheimer’s Drug Discovery Foundation (ADDF) have teamed up to support Wave Life Sciences’ FOCUS-C9 Phase 1b/2a clinical trial, which is looking at WVE-004 as a potential treatment for C9orf72-associated frontotemporal degeneration (C9-FTD) and amyotrophic lateral sclerosis (C9-ALS)
• In July 2021, For the development and commercialization of two clinical-stage, potentially first-in-class monoclonal antibodies (AL001 and AL101) intended to increase progranulin (PGRN) levels, GlaxoSmithKline plc and Alector embarked into a strategic global collaboration 

Frontotemporal Dementia Overview

A collection of disorders collectively known as frontotemporal dementia (FTD) are caused by the gradual brain deterioration of the frontal and temporal lobes. These brain regions are important for behaviour, language, and decision-making skills.

Get a Free Sample PDF Report to know more about Frontotemporal Dementia Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/frontotemporal-dementia-pipeline-insight

Emerging Frontotemporal Dementia Drugs Under Different Phases of Clinical Development Include:

• Research programme CNS Therapies: Deep Genomics
• AS-203: AcuraStem
• Research Programme: M1 PAM: Asceneuron SA
• AVB PGRN: AviadoBio
• Research programme: CNS therapeutics: CAMP4 Therapeutics
• NI308: Neurimmune
• PR 006: Prevail Therapeutics
• Latozinemab: Alector
• PBFT-02: Passage Bio
• EXO-050: Coya Therapeutics
• WVE-004: Wave Life Sciences
• PBFT02: Passage Bio
• PR006: Prevail Therapeutics
• TPN-101: Transposon Therapeutics
• AL001: Alector Inc

Route of Administration

Frontotemporal Dementia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types, such as

• Oligonucleotide
• Peptide
• Small molecule 

Frontotemporal Dementia Pipeline Therapeutics Assessment

• Frontotemporal Dementia Assessment by Product Type
• Frontotemporal Dementia By Stage and Product Type
• Frontotemporal Dementia Assessment by Route of Administration
• Frontotemporal Dementia By Stage and Route of Administration
• Frontotemporal Dementia Assessment by Molecule Type
• Frontotemporal Dementia by Stage and Molecule Type

DelveInsight’s Frontotemporal Dementia Report covers around 25+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Frontotemporal Dementia product details are provided in the report. Download the Frontotemporal Dementia pipeline report to learn more about the emerging Frontotemporal Dementia therapies

Some of the key companies in the Frontotemporal Dementia Therapeutics Market include:

Key companies developing therapies for Frontotemporal Dementia are – Alector, Prevail Therapeutics, Passage Bio, Inc., Wave Life Sciences Ltd., CAMP4 Therapeutics, Coya Therapeutics, SOLA Biosciences, AcuraStem, Denali Therapeutics, Wave Life Sciences, Neurimmune, Biogen, Asceneuron SA, Libra Therapeutics, Muna Therapeutics, Alkermes, DEEP GENOMICS, Sangamo Therapeutics, LOCANABIO, Arkuda Therapeutics, Yumanity, Autifony Therapeutics, Prothena, Mabylon AG  and others.

Frontotemporal Dementia Pipeline Analysis:

The Frontotemporal Dementia pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Frontotemporal Dementia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Frontotemporal Dementia Treatment.
• Frontotemporal Dementia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Frontotemporal Dementia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Frontotemporal Dementia market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Frontotemporal Dementia drugs and therapies

Frontotemporal Dementia Pipeline Market Drivers

• Increasing prevalence of giatric population, increasing drug development grants, increasing collaborations among companies are some of the important factors that are fueling the Frontotemporal Dementia Market.

Frontotemporal Dementia Pipeline Market Barriers

• However, lack of proper diagnosis, higher chances of misunderstanding with Alzheimer’s disease and other factors are creating obstacles in the Frontotemporal Dementia Market growth.

Scope of Frontotemporal Dementia Pipeline Drug Insight    

• Coverage: Global
• Key Frontotemporal Dementia Companies: Deep Genomics, AcuraStem, Asceneuron SA, AviadoBio, CNS therapeutics, CAMP4 Therapeutics, Neurimmune, Wave Life Sciences, Passage Bio, Prevail Therapeutics, Transposon Therapeutics, Alector Inc, and others
• Key Frontotemporal Dementia Therapies: Research programme CNS Therapies, AS-203, M1 PAM, AVB PGRN, NI308, WVE-004, PBFT02, PR006, TPN-101, AL001, and others
• Frontotemporal Dementia Therapeutic Assessment: Frontotemporal Dementia current marketed and Frontotemporal Dementia emerging therapies
• Frontotemporal Dementia Market Dynamics: Frontotemporal Dementia market drivers and Frontotemporal Dementia market barriers 

Request for Sample PDF Report for Frontotemporal Dementia Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services